WO2005097103A3 - Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors - Google Patents

Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors Download PDF

Info

Publication number
WO2005097103A3
WO2005097103A3 PCT/US2005/011065 US2005011065W WO2005097103A3 WO 2005097103 A3 WO2005097103 A3 WO 2005097103A3 US 2005011065 W US2005011065 W US 2005011065W WO 2005097103 A3 WO2005097103 A3 WO 2005097103A3
Authority
WO
WIPO (PCT)
Prior art keywords
cathepsin
diabetes
inhibitors
metabolic syndrome
therapy utilizing
Prior art date
Application number
PCT/US2005/011065
Other languages
French (fr)
Other versions
WO2005097103A2 (en
Inventor
Samuel E Broder
Robert M Rydzewski
Original Assignee
Axys Pharm Inc
Samuel E Broder
Robert M Rydzewski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc, Samuel E Broder, Robert M Rydzewski filed Critical Axys Pharm Inc
Publication of WO2005097103A2 publication Critical patent/WO2005097103A2/en
Publication of WO2005097103A3 publication Critical patent/WO2005097103A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to the treatment of Type II diabetes by administering a cathepsin B inhibitor(s).
PCT/US2005/011065 2004-04-01 2005-04-01 Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors WO2005097103A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55893304P 2004-04-01 2004-04-01
US60/558,933 2004-04-01

Publications (2)

Publication Number Publication Date
WO2005097103A2 WO2005097103A2 (en) 2005-10-20
WO2005097103A3 true WO2005097103A3 (en) 2006-08-10

Family

ID=34979661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011065 WO2005097103A2 (en) 2004-04-01 2005-04-01 Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors

Country Status (1)

Country Link
WO (1) WO2005097103A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010885A1 (en) * 2005-07-19 2007-01-25 Daiichi Sankyo Company, Limited Substituted propanamide derivative and pharmaceutical composition containing the same
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2010069069A1 (en) * 2008-12-17 2010-06-24 Merck Frosst Canada Ltd. Cathepsin b inhibitors
EP2408455B1 (en) 2009-03-20 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CN107690429B (en) * 2015-04-07 2022-02-25 Ela制药有限公司 Composition for the treatment and/or prevention of necrosis of cells or tissue, specifically targeting cathepsin C and/or CELA1 and/or CELA3A and/or enzymes structurally related thereto
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026851A1 (en) * 2002-09-20 2004-04-01 Axys Pharmaceuticals, Inc. 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026851A1 (en) * 2002-09-20 2004-04-01 Axys Pharmaceuticals, Inc. 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CUMMINS, CAROLYN L. ET AL: "Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS , 300(3), 1036-1045 CODEN: JPETAB; ISSN: 0022-3565, 2002, XP002379538 *
SWEENEY DEACON ET AL: "Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents.", BIOCHEMICAL PHARMACOLOGY, vol. 66, no. 4, 15 August 2003 (2003-08-15), pages 663 - 677, XP008063830, ISSN: 0006-2952 *

Also Published As

Publication number Publication date
WO2005097103A2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2005097103A3 (en) Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
PT1928499E (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
WO2007127263A3 (en) Therapeutic uses of urolithins
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2008033562A3 (en) Kinase inhibitor compounds
WO2007022518A8 (en) New uses of glucoregulatory proteins
MY170728A (en) Treatment for diabetes in patients inappropriate for metformin therapy
IL192103A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
WO2007101232A3 (en) Inhibition of jak2 as a treatment of pulmonary arterial hypertension
WO2008156701A3 (en) Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2005074904A3 (en) Silinane compounds as cysteine protease inhibitors
MX2007006279A (en) Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors.
WO2007047205A8 (en) Enzyme inhibitors of pai-1
WO2008125800A3 (en) Mmp activated vascular disrupting agents
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
WO2007095611A3 (en) Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
SE0200198D0 (en) New use
WO2007022138A3 (en) Genistein inhibition of transthyretin amyloidosis
DK1675611T3 (en) Therapeutic uses for C-peptide
NO20071330L (en) Enzyme inhibitor in leukemia
WO2007123847A3 (en) Treatment of melanoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase